Supportive Care in Cancer

, Volume 16, Issue 4, pp 329–337 | Cite as

The management of dyspnea in cancer patients: a systematic review

  • Raymond Viola
  • Cathy Kiteley
  • Nancy S. Lloyd
  • Jean A. Mackay
  • Julie Wilson
  • Rebecca K. S. Wong
  • Supportive Care Guidelines Group of the Cancer Care Ontario Program in Evidence-Based Care
Review Article

Abstract

Goals of work

The goal of the study is to evaluate the effectiveness of four drug classes (opioids, phenothiazines, benzodiazepines, and systemic corticosteroids) for relieving dyspnea experienced by advanced cancer patients.

Materials and methods

A systematic literature review was conducted to July 2006. Search sources included MEDLINE, EMBASE, HealthSTAR, CINAHL, and the Cochrane Library. Four reviewers selected evidence using predefined criteria: controlled trials not limited to cancer and involving the specified drug classes for dyspnea treatment.

Main results

Three systematic reviews, one with meta-analysis, two practice guidelines, and 28 controlled trials were identified. Most examined the effect of opioids, generally morphine, on dyspnea. Although the results of individual trials were mixed, the systematic review with meta-analysis detected a significant benefit for dyspnea with systemic opioids; two small placebo-controlled trials in cancer patients found systemic morphine reduced dyspnea, and dihydrocodeine also significantly reduced dyspnea in four placebo-controlled trials. Nebulized morphine was not effective in controlling dyspnea in any study or the meta-analysis. No controlled trials examined systemic corticosteroids in the treatment of cancer patients, and of the other non-opioid drugs examined, only oral promethazine, a phenothiazine, showed some benefit in the relief of dyspnea. Studies varied in methodological quality.

Conclusions

Systemic opioids, administered orally or parenterally, can be used to manage dyspnea in cancer patients. Oral promethazine may also be used, as a second-line agent if systemic opioids cannot be used or in addition to systemic opioids. Nebulized morphine, prochlorperazine, and benzodiazepines are not recommended for the treatment of dyspnea, and promethazine must not be used parenterally.

Keywords

Systematic review Dyspnea Treatment Cancer 

Notes

Acknowledgements

The Program in Evidence-Based Care is supported by, but editorially independent of, Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care. No potential conflicts of interest with regard to this review were declared by the authors.

References

  1. 1.
    Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C (2003) Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. Br Med J 327:523–526CrossRefGoogle Scholar
  2. 2.
    Allard P, Lamontagne C, Bernard P, Tremblay C (1999) How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 17:256–265PubMedCrossRefGoogle Scholar
  3. 3.
    Barsevick AM, Whitmer K, NailL M, Beck SL, Dudley WN (2006) Symptom cluster research: conceptual, design, measurement, and analysis issues. J Pain Symptom Manage 31:85–95PubMedCrossRefGoogle Scholar
  4. 4.
    Beauford W, Saylor TT, Stansbury DW, Avalos K, Light RW (1993) Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest 104:175–178PubMedCrossRefGoogle Scholar
  5. 5.
    Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218Google Scholar
  6. 6.
    Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafni A et al (1995) The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 13:502–512PubMedGoogle Scholar
  7. 7.
    Bruera E, MacEachern T, Ripamonti C, Hanson J (1993) Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 119:906–907PubMedGoogle Scholar
  8. 8.
    Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, Willey J (2005) Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage 29:613–618PubMedCrossRefGoogle Scholar
  9. 9.
    Buck C, Laier-Groeneveld G, Criee CP (1996) The effect of dihydrocodeine and terbutaline on breathlessness and inspiratory muscle function in normal subjects and patients with COPD [abstract]. Eur Respir J 9:344sGoogle Scholar
  10. 10.
    Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson PA, Coats AJ (1997) Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 29:147–152PubMedCrossRefGoogle Scholar
  11. 11.
    Davis CL (1996) Single-dose randomized controlled trial of nebulized morphine in patients with cancer-related breathlessness [abstract]. Palliative Med 10:64–65Google Scholar
  12. 12.
    Donnelly S, Walsh D (1995) The symptoms of advanced cancer. Sem Oncol 22(2 Suppl 3):67–72Google Scholar
  13. 13.
    Dudgeon DJ (2002) Managing dyspnea and cough. Hematol Oncol Clin N Am 16:557–577CrossRefGoogle Scholar
  14. 14.
    Eimer M, Cable T, Gal P, Rothenberger LA, McCue JD (1985) Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. J Fam Pract 21:359–362PubMedGoogle Scholar
  15. 15.
    Eiser N, Denman WT, West C, Luce P (1991) Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer” syndrome. Eur Respir J 4:926–931PubMedGoogle Scholar
  16. 16.
    Finnish Medical Society Duodecim (2005) Palliative treatment of cancer. EBM guidelines. Evidence-based medicine.Helsinki, Finland: Duodecim Medical Publications LtdGoogle Scholar
  17. 17.
    Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD (1995) Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med 152:1940–1945PubMedGoogle Scholar
  18. 18.
    Institute for Safe Medication Practices (2006) Action needed to prevent serious tissue injury with IV promethazine. Available at: http://www.ismp.org/Newsletters/acutecare/articles/20060810.asp Accessed: 17 Oct 2006
  19. 19.
    Jadad AR (1998) Randomized controlled trials. BMJ, LondonGoogle Scholar
  20. 20.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17:1–12PubMedCrossRefGoogle Scholar
  21. 21.
    Jankelson D, Hosseini K, Mather LE, Seale JP, Young IH (1997) Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J 10:2270–2274PubMedCrossRefGoogle Scholar
  22. 22.
    Jennings A-L, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE (2002) A systematic review of the use of opioids in the management of dyspnoea. Thorax 57:939–944PubMedCrossRefGoogle Scholar
  23. 23.
    Johnson MA, Woodcock AA, Geddes DM (1983) Dihydrocodeine for breathlessness in “pink puffers”. Br Med J (Clin Res Ed) 286:675–677Google Scholar
  24. 24.
    Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ (2002) Morphine for the relief of breathlessness in patients with chronic heart failure—a pilot study. Eur J Heart Fail 4:753–756PubMedCrossRefGoogle Scholar
  25. 25.
    Joyce M, McSweeney M, Carrieri-Kohlman VL, Hawkins J (2004) The use of nebulized opioids in the management of dyspnea: evidence synthesis. Oncol Nurs Forum 31:551–561PubMedCrossRefGoogle Scholar
  26. 26.
    Krouse RS, Rosenfeld KE, Grant M, Aziz N, Byock I, Sloan J et al (2004) Palliative care research: issues and opportunities. Cancer Epidmiol Biomarkers Prev 13:337–339Google Scholar
  27. 27.
    Kvale PA, Simoff M, Prakash UB (2003) Lung cancer, palliative care. Chest 123(1 Suppl):284S–311SPubMedCrossRefGoogle Scholar
  28. 28.
    Leung R, Hill P, Burdon J (1996) Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax 51:596–600PubMedGoogle Scholar
  29. 29.
    Light RW, Muro JR, Sato RI, Stansbury DW, Fischer CE, Brown SE (1989) Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 139:126–133PubMedGoogle Scholar
  30. 30.
    Light RW, Stansbury DW, Webster JS (1996) Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest 109:975–981PubMedCrossRefGoogle Scholar
  31. 31.
    Man GC, Hsu K, Sproule BJ (1986) Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 90:832–836PubMedCrossRefGoogle Scholar
  32. 32.
    Masood AR, Reed JW, Thomas SHL (1995) Lack of effect of inhaled morphine on exercise induced breathlessness in chronic obstructive pulmonary disease. Thorax 50:629–634PubMedGoogle Scholar
  33. 33.
    Mazzocato C, Buclin T, Rapin C-H (1999) The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol 10:1511–1514PubMedCrossRefGoogle Scholar
  34. 34.
    Mitchell-Heggs P, Murphy K, Minty K, Guz A, Patterson SC, Minty PS et al (1980) Diazepam in the treatment of dyspnoea in the ‘Pink Puffer’ syndrome. Q J Med 49:9–20PubMedGoogle Scholar
  35. 35.
    Navigante AH, Cerchietti LC, Castro MA, Lutteral MA, Cabalar ME (2006) Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 31:38–47PubMedCrossRefGoogle Scholar
  36. 36.
    Noseda A, Carpiaux J-P, Markstein C, Meyvaert A, de M, V (1997) Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J 10:1079–1083PubMedCrossRefGoogle Scholar
  37. 37.
    Peterson GM, Young RS, Dunne PF, Galloway JG, Parks TE (1996) Pilot study of nebulised morphine for dyspnoea in palliative care patients. Aust J Hosp Pharm 26:545–547Google Scholar
  38. 38.
    Polosa R, Simidchiev A, Walters EH (2002) Nebulised morphine for severe interstitial lung disease. Cochrane Database of Systematic Reviews Issue 3.:Art. No.:CD002872. DOI  10.1002/14651858.CD002872
  39. 39.
    Poole PJ, Veale AG, Black PN (1998) The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1877–1880PubMedGoogle Scholar
  40. 40.
    Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE (1987) Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 81:287–292PubMedCrossRefGoogle Scholar
  41. 41.
    Thomas JR, von Gunten CF (2003) Management of dyspnea. J Support Oncol 1:23–32PubMedGoogle Scholar
  42. 42.
    Vainio A, Auvinen A, Symptom Prevalence Group (1996) Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manage 12:3–10PubMedCrossRefGoogle Scholar
  43. 43.
    Vickers AJ, Feinstein MB, Deng GE, Cassileth BR (2005) Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial [ISRCTN89462491]. BMC palliative care 4:5:DOI  10.1186/1472-684X-4-5
  44. 44.
    Wickham R, Malec M (2003) Management of dyspneaPeer viewpoint. J Support Oncol 1:32–34Google Scholar
  45. 45.
    Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JAE (2005) Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews Issue 1.:Art. No.: CD001288. DOI  10.1002/14651858.CD001288.pub2
  46. 46.
    Woodcock AA, Gross ER, Geddes DM (1981) Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J (Clin Res Ed) 283:343–346CrossRefGoogle Scholar
  47. 47.
    Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM (1981) Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 305:1611–1616PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Raymond Viola
    • 1
  • Cathy Kiteley
    • 2
  • Nancy S. Lloyd
    • 3
  • Jean A. Mackay
    • 3
  • Julie Wilson
    • 3
  • Rebecca K. S. Wong
    • 4
  • Supportive Care Guidelines Group of the Cancer Care Ontario Program in Evidence-Based Care
  1. 1.Palliative Care Medicine ProgramQueen’s UniversityKingstonCanada
  2. 2.Credit Valley HospitalMississaugaCanada
  3. 3.McMaster University/Cancer Care Ontario Program in Evidence-Based CareHamiltonCanada
  4. 4.Department of Radiation OncologyPrincess Margaret HospitalTorontoCanada

Personalised recommendations